Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Wahner Hendrickson

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2009
Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapyAndrea Wahner Hendrickson, Paul Haluska
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Current and Future Directions for PARP InhibitionMegan Grudem, Andrea Wahner Hendrickson
Critical Care Clinics|December 1, 2009
Oncologic emergenciesDeepti Behl, Andrea Wahner Hendrickson, Timothy J Moynihan
The Journal of Clinical Investigation|October 25, 2008
Anticancer therapy: boosting the bang of BimAndrea Wahner Hendrickson, Xue Wei Meng, Scott H Kaufmann
CA: a Cancer Journal for Clinicians|August 23, 2011
Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatmentMark A Lewis, Andrea Wahner Hendrickson, Timothy J Moynihan
The American Journal of Hospice & Palliative Care|July 19, 2019
Loratadine for Paclitaxel-Induced Myalgias and ArthralgiasCaleb Smith, Andrea Wahner Hendrickson, Megan Grudem, et al.
The American Journal of Hospice & Palliative Care|July 10, 2018
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?Ryan A Balko, Andrea Wahner Hendrickson, Megan E Grudem, et al.
Women'S Health (London, England)|September 29, 2020
Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovationAriela L Marshall, Virginia Dines, Andrea Wahner Hendrickson, et al.
American Journal of Clinical Oncology|October 20, 2025
A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian CancerAminah Jatoi, Nathan R Foster, Andrea Wahner Hendrickson, et al.
Oncology|December 16, 2014
A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patientsAminah Jatoi, Carmen Radecki Breitkopf, Nathan R Foster, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|September 25, 2009
Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapyAndrea Wahner Hendrickson, Paul Haluska
Journal of the Advanced Practitioner in Oncology|February 18, 2021
Current and Future Directions for PARP InhibitionMegan Grudem, Andrea Wahner Hendrickson
Critical Care Clinics|December 1, 2009
Oncologic emergenciesDeepti Behl, Andrea Wahner Hendrickson, Timothy J Moynihan
The Journal of Clinical Investigation|October 25, 2008
Anticancer therapy: boosting the bang of BimAndrea Wahner Hendrickson, Xue Wei Meng, Scott H Kaufmann
CA: a Cancer Journal for Clinicians|August 23, 2011
Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatmentMark A Lewis, Andrea Wahner Hendrickson, Timothy J Moynihan
The American Journal of Hospice & Palliative Care|July 19, 2019
Loratadine for Paclitaxel-Induced Myalgias and ArthralgiasCaleb Smith, Andrea Wahner Hendrickson, Megan Grudem, et al.
The American Journal of Hospice & Palliative Care|July 10, 2018
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?Ryan A Balko, Andrea Wahner Hendrickson, Megan E Grudem, et al.
Women'S Health (London, England)|September 29, 2020
Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovationAriela L Marshall, Virginia Dines, Andrea Wahner Hendrickson, et al.
American Journal of Clinical Oncology|October 20, 2025
A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian CancerAminah Jatoi, Nathan R Foster, Andrea Wahner Hendrickson, et al.
Oncology|December 16, 2014
A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patientsAminah Jatoi, Carmen Radecki Breitkopf, Nathan R Foster, et al.
Pageof 2